Key result
Aliskiren shows antiproteinuric effects in patients with CKD.
Why the study?
Does aliskiren reduce proteinuria and delay disease progression in patients with chronic kidney disease?
Does aliskiren reduce proteinuria and delay disease progression in patients with chronic kidney disease?
Aliskiren, a direct renin inhibitor, demonstrates antiproteinuric effects and may offer an additional strategy to suppress the RAAS system in chronic kidney disease.
Aliskiren may reduce proteinuria in CKD; leaves open effects on progression pending randomized trials.
The renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathogenesis of hypertension, cardiovascular diseases (CVDs) and chronic kidney disease (CKD). Drugs affecting the RAAS system, such as angiotensinconverting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), are commonly used in the treatment of hypertension and heart failure. These drugs are also effective in reducing proteinuria and may, at least, delay end-stage renal disease in both diabetic and non-diabetic proteinuric CKD. However, novel drugs are needed to more effectively suppress the RAAS system and the progression of CKD. Aliskiren is the first direct renin inhibitor which has been approved for the treatment of hypertension. Additionally, a number of clinical studies have shown the antiproteinuric effect of aliskiren.
No takes yet. Share an insight, caveat, or question.
Łukawski et al. (2017) conducted a review in Chronic kidney disease and hypertension. Aliskiren was evaluated. Aliskiren, a direct renin inhibitor approved for hypertension, has been shown in clinical studies to have an antiproteinuric effect in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: